Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Philip J. Meacham"'
Autor:
Dina, Mikdadi, Kyle A, O'Connell, Philip J, Meacham, Madeleine A, Dugan, Michael O, Ojiere, Thaddeus B, Carlson, Juergen A, Klenk
Publikováno v:
Cancer Biomarkers. 33:173-184
BACKGROUND: Artificial intelligence (AI), including machine learning (ML) and deep learning, has the potential to revolutionize biomedical research. Defined as the ability to “mimic” human intelligence by machines executing trained algorithms, AI
Autor:
Bahar Moftakhar, Bryan Fitzgerald, Manidhar Lekkala, Myla Strawderman, Philip J. Meacham, Tae C Smith, Ajay Dhakal
Publikováno v:
Cancer Research. 80:P1-19
Background: Palbociclib (palbo), a CDK4/6 inhibitor, is commonly added to an aromatase inhibitor (AI) as the first line therapy in managing estrogen receptor positive, HER2 non amplified (ER+ HER2-) metastatic breast cancer (MBC). Though more tolerab
Publikováno v:
Leukemia & Lymphoma. 61:1037-1051
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is associated with increased risk for certain cancers, but relatively little is known about the risk for these patients to develop additional B cell malignancies. Here, we review the
Autor:
Bryan Fitzgerald, Ajay Dhakal, Myla Strawderman, Manidhar Lekkala, Carla I. Falkson, Tae C Smith, Philip J. Meacham, Bahar Moftakhar
Publikováno v:
Breast cancer research and treatment. 183(2)
Palbociclib is commonly added to an aromatase inhibitor (AI) as first-line therapy in ER + HER2- metastatic breast cancer (MBC). There are no data on the effect of the relative dose intensity (RDI) of palbociclib in first-line setting on clinical out
Autor:
Clive S. Zent, Philip J. Meacham, AnnaLynn M. Williams, Danielle Wallace, Nicholas P. Tschernia, Walter Richard Burack, Paul M. Barr, Myla Strawderman, William J. Archibald, Andrea Baran
Publikováno v:
Leukemialymphoma. 61(7)
Family and migration studies suggest a genetic risk of developing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). We hypothesized that CLL patients have an increased risk of additional clonally unrelated B-cell malignancies. To test th
Autor:
Paul M. Barr, Clive S. Zent, Andrea Baran, Jeremiah Moore, Philip J. Meacham, Andrew G. Evans
Publikováno v:
American journal of hematology. 95(5)
Autor:
Marina Oktapodas Feiler, Conrad F. Shamlaye, Alison J. Yeates, Edwin van Wijngaarden, Philip J. Meacham, Huiqi Li, Karin Broberg, Deven Patel, Gene E. Watson
Publikováno v:
NeuroToxicology. 65:22-27
Purpose To examine the association between telomere length and neurodevelopment in children. Methods We examined the relationship between relative telomere length (rTL) and neurodevelopmental outcomes at 9 and 30 months, and 5 years of age in childre
Autor:
Paul M. Barr, Shuo Ma, Clive S. Zent, Andrea M. Baran, Andrew Bui, Philip J Meacham, Ashley Morrison, Kelsey Holkovic, Jane L. Liesveld, Deborah A Mulford, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Brian T. Hill
Publikováno v:
Blood. 136:41-42
Background: Despite the effectiveness of novel agents in treating CLL, prolonged single agent use can lead to drug resistance, toxicity, challenges with adherence, and considerable financial burden. Combinations may provide deeper prolonged remission
Autor:
Paul M. Barr, Megan M. Herr, Philip J. Meacham, Laurie A. Milner, Jonathan W. Friedberg, Michael W. Becker, Bradley D. Hunter, Carla Casulo, Louis S. Constine, Andrew G. Evans, Ferdous Barlaskar, Sughosh Dhakal, Jane L. Liesveld, W. Richard Burack
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:145-151
Background The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Evidence has suggested that early relapses (ie, within 1 year) aft
Autor:
Paul G. Rothberg, AnnaLynn M. Williams, Jeremiah Moore, Philip J. Meacham, Clive S. Zent, Margaret J. Helber
Publikováno v:
American Journal of Hematology. 92:E542-E544